January 23, 2021

The Niche

Trusted stem cell blog & resources

Mesoblast

3 min read

Over at the Harvard Law “Bill of Health” blog, Mary Ann Chirba and Alice A. Nobel posted a piece entitled “Our Bodies, Our Cells” a few days ago that has generated a lot of discussion about FDA regulation of stem cell interventions. Their piece really has two parts. In the first part they go through the US v. Regenerative Sciences Inc. (RSI) case providing helpful and insightful perspectives on the history of the case and their prediction as to the likely outcome on appeal. …Read More

1 min read

Allan Robins of Viacyte (pictured at left–sorry for the fuzzy image) and Paul Simmons of Mesoblast presented this morning at the CIRM Grantee Meeting. Both talks were outstanding. Robins went first. He started by saying how Viacyte had a productive pre-IND meeting with the FDA last year. I believe a target for them is to have IND in Q1 of 2014 and hopefully move to the clinical trials soon after. I gotta say I love Viacyte’s technology. Having a frozen product that then can …Read More